FHAM
SAGE

Folger Hill Asset Management’s Sage Therapeutics SAGE Stock Holding History

Folger Hill Asset Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-75,000
Closed -$5.33M – 348
2017
Q1 		$5.33M Sell
75,000
-25,000
-25% -$1.46M 0.43% 80
2016
Q4 		$5.11M Buy
+100,000
New +$4.71M 0.46% 83

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Folger Hill Asset Management's SAGE Position: Q3 2017 in Review

Folger Hill Asset Management sold out of Sage Therapeutics (SAGE) in Q3 2017, closing a stake of 41,471 shares — an estimated $3.3M sold.

Folger Hill Asset Management first reported a position in SAGE in Q2 2016 and held it in 5 quarters. The position peaked at $8.95M in Q1 2017. 174 funds tracked by Wall St. Rank hold SAGE as of Q3 2017.

  • Folger Hill Asset Management reported no remaining Sage Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Folger Hill Asset Management sold 41,471 Sage Therapeutics shares in Q3 2017, an estimated $3.3M.
  • Folger Hill Asset Management first reported a position in Sage Therapeutics in Q2 2016 and held it in 5 quarters.
  • Folger Hill Asset Management's Sage Therapeutics position peaked at $8.95M in Q1 2017.
  • 174 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2017.

Based on Folger Hill Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.